Trilostane

Drug Profile

Trilostane

Alternative Names: Abetafen; Modrastane; Modrefen; Modrenal

Latest Information Update: 14 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stegram Pharmaceuticals
  • Class Androstanols; Testosterone congeners
  • Mechanism of Action 3-hydroxysteroid dehydrogenase inhibitors; Estrogen receptor antagonists; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • No development reported Adrenal cortical hyperfunction; Prostate cancer
  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 08 Sep 2009 No development reported - Clinical for Breast cancer in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top